6th Jun 2007 07:02
AstraZeneca PLC06 June 2007 AstraZeneca CFO to join Goldman Sachs AstraZeneca PLC announces the resignation of its Chief Financial Officer, JonSymonds, with effect from the end of July. Jon Symonds joined Zeneca in 1997 asCFO after 17 years at KPMG. Within months of joining, he was involved in themerger negotiations with Swedish pharmaceutical company, Astra. Aftercompletion of the merger in 1998, Jon was appointed as CFO for AstraZeneca PLC. "Jon has played a critical role in driving AstraZeneca to become one of theleading, most focused and most successful pharmaceutical companies in the world.On a personal level, I have worked closely with him for several years and havevalued his knowledge of the business, strategic thinking, and wise financialcounsel enormously," said David Brennan, CEO. Jon leaves AstraZeneca to join global investment banking, securities andinvestment management firm, Goldman Sachs in mid September as a managingdirector. His legacy at AstraZeneca includes a record of consistent strongfinancial performance and a mature, well structured global Finance leadershipteam. Louis Schweitzer, Chairman, commented, "I have the utmost respect for Jon'spersonal and professional capabilities, he carries significant credit both forthe success of the merger itself and for AstraZeneca's sound financialperformance since 1998. I regret Jon's decision to leave AstraZeneca, however,the move to Goldman Sachs represents an exciting career challenge for him and Iwish him every success with it." An external search is underway to identify a successor. -Ends- June 6th 2007 Media Enquiries:Edel McCaffrey, Tel: +44 (0) 207 304 5034Steve Brown, Tel: +44 (0) 207 304 5033 Investor Relations:Mina Blair, Tel: +44 (0) 207 304 5084Jonathan Hunt, Tel: +44 (0) 207 304 5087 Karl Hard, Tel: +44 (0) 207 304 5322Jorgen Winroth, Tel: +1 (212) 579 0506Ed Seage, Tel: +1 302 886 4065 Goldman Sachs: Paul Kafka, Tel: +44(0) 207 774 4667 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca